Fresenius SE & Co. KGaA

Investor Presentation • Mar 11, 2021

Barclays Global Healthcare Conference

March 11, 2021

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing.

Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Agenda

3

A Global Leader in Health Care Products and Services

Investment Highlights

Global Trends offer Growth Opportunities for Fresenius

Sources: 1 UN, 2019 Revision of World Population Prospects (2019) 2 UBS, Longer Term Investments: EM healthcare (2018) 3 IDF Diabetes Atlas (2017) 4 AAM report (2019) 5 UBS, Longer Term Investments: Generics (2018)

The Fresenius Strategy

Strategic Roadmap

¹ Plus ~1% small to mid-sized acquisitions

Growth Areas

Environment, Social and Governance Setting the right priorities in a COVID-19 world

"Better medicine for more people"

Ensuring access to medicine

Protecting our employees

Alignment with SDGs published on website

ESG priorities confirmed Sustainability progress in 2020 Corporate governance update

Rating improvements across the board, Highlights: CDP Climate from "C" to "B", MSCI from "BB" to "BBB"

Restructured, GRI-aligned sustainability report to be released in March 2021

Strategy and KPI alignment program to be continued in 2021, driven by Group Sustainability Board

New Management Board remuneration system to be presented at AGM, includes ESG component

Supervisory Board elections on AGM agenda

Environment, Social and Governance

Refreshed Materiality analysis in 2020 - core priorities confirmed, new topics added

ESG Rating Overview Continuous Improvement through Reporting and Engagement

Fresenius Group: Global Sales Base in Growing, Non-Cyclical Markets

Before special items 2016-2018 excluding IFRS 16

Strong track record of organic sales growth

Strong and Balanced Health Care Portfolio

Ownership: ~32% Ownership: 100% Ownership: 100% Ownership: 77%

Dialysis Products Health Care Services

• Dialysis services
• Hemodialysis products
• Peritoneal dialysis products
• Care coordination

• IV drugs
• Clinical nutrition
  • Infusion therapy
  • Medical devices/ Transfusion technology
  • Biosimilars

Sales 2020: €17.9 bn

Sales 2020: €7.0 bn

Hospital Supplies Hospital Operation Projects and Services for Hospitals

• Post-acute care
• Project development & Planning
• Turnkey construction
• Maintenance & Technical and total operational management

Sales 2020: €9.8 bn

• Outpatient services

• Acute care

Sales 2020: €2.1 bn

Fresenius Medical Care: Global Dialysis Market Leader

• The world's leading provider of dialysis products and services treating ~347,000 patients1 in ~4,000 clinics1
• Provide highest standard of product quality and patient care

Dialysis products

Dialysis services

Complete therapy offerings

• Expansion in Care Coordination and global dialysis service opportunities; enter new geographies

Market Dynamics

Increase in worldwide demand

• Sustainable business based on high quality products and ~ 3% Patient growth in 2020 + 37% Growth of home hemodialysis treatments in 2020 in the U.S.

• Strong global footprint Global market for dialysis products and services

• Leading market positions ~ € 82 bn

services

• Highly qualified employees Big Data is driving new treatment models

• High level of vertical integration ~ 54 million

dialysis treatments in 2020 providing sound data basis to further standardize medical setups at Fresenius Medical Care

¹ As of December 31, 2020

Fresenius Kabi: A Leading Global Hospital Supplier

Market Dynamics • Comprehensive product portfolio for critically and chronically ill patients • Strong Emerging Markets presence • Leading market positions Emerging Markets 31% Sales 2020: €7.0 bn North America 34% Europe 35% Generic IV Drugs Clinical Nutrition Infusion Therapy Medical Devices / Transfusion Technology Biosimilars Growing healthcare spending in Emerging Markets +6.3% p.a. growth over the next decade Aging population 16% of the world population will be > age 65 by 2050 (9% in 2019) Rising cost consciousness in healthcare spending – significant savings from generics ~US\$293bn p.a. savings in the US ~ €100bn p.a. savings in the EU • Focus on organic growth through geographic product rollouts and new product launches • Development of biosimilars with a focus on oncology and autoimmune diseases Sales by Region

Fresenius Helios: Europe's Largest Private Hospital Operator

• Market leader in size and quality with excellent growth prospects
• ~5%1 share in German acute care hospital ~12%1 share in Spanish private hospital market
• Quality is key: defined quality targets, publication of medical treatment results, peer review processes
• Broad revenue base with public and privately insured patients, PPPs, self-pay and Occupational Risk Prevention

Acute Care

Outpatient

Occupational Risk Prevention

• Development of new business models to foster digitalization and profit from trend towards outpatient treatments

Market Dynamics

Hospital market in Germany ~ € 109 bn

Length of stay below the average of 7.2 days

in Germany provides benefits for hospital operators

(Helios Germany: 5.7 days)

Private hospital market in Spain ~ € 16 bn

Average increase of private health insurance policies in Spain of ~2.5% p.a.

¹ Based on sales

Fresenius Vamed: Leading Global Hospital Projects and Services Specialist

• Manages hospital construction/expansion projects and provides services for health care facilities worldwide
• Offers project development, planning, turnkey construction, maintenance as well as technical management, and total operational management
• Strong track record: More than 900 projects in over 90 countries completed

Projects

Services

Post-acute care

¹ As of December 31, 2020

• Leading European post-acute care provider operating in five European countries
• Sales by product segment shifted in recent years towards the service business:
  • Service business: 69%1
  • Project business: 31%1

Market Dynamics

Telemedicine market in Europe is estimated to grow

14.1% p.a. till 2025.

Global preventive health care is estimated to grow

9.5% p.a. till 2025.

Outsourcing of non-medical services provided by public institutions to private providers grew in Germany by

50% from 2013 to 2018.

Emerging markets' share of global health expenditure will grow to

33% by 2022.

Fresenius Group: Medium-term Growth Targets 2020 – 2023 (CAGRs)

¹ Net income attributable to shareholders of Fresenius SE & Co.KGaA Before special items

Fresenius SE: Earnings-Linked Dividend Policy

¹ Proposal ² Before special items

Fresenius Share & Shareholder Structure

Analyst recommendations

Shareholder structure by investors

Share price development LTM

Shareholder structure by region

As of December 31, 2020

FRE Historical share price performance

Agenda

24

Strong track record of organic sales growth

Strategic Roadmap

¹ Plus ~1% small to mid-sized acquisitions

Cost-efficiency program to be initiated

• Streamlining activities in organizational structures and facilities/real estate and other synergy fields

• Efficiency improvements globally and identification of other savings in indirect spend
• Review of cost structures particularly in markets with significant price pressure

• Review of non-medical support processes and structures
• Strategic alignment of clinic portfolio in Germany

• Review of assets and shareholdings portfolio

• Implementation of new ways of working for corporate headquarters
• Groupwide review of IT operating model Corporate

Savings of at least €100 m p.a. after tax and minorities planned in 2023

Biosimilars gaining traction and will significantly accelerate growth

Environment, Social and Governance Setting the right priorities in a COVID-19 world

"Better medicine for more people"

Ensuring access to medicine

Protecting our employees

Alignment with SDGs published on website

ESG priorities confirmed Sustainability progress in 2020 Corporate governance update

Rating improvements across the board, Highlights: CDP Climate from "C" to "B", MSCI from "BB" to "BBB"

Restructured, GRI-aligned sustainability report to be released in March 2021

Strategy and KPI alignment program to be continued in 2021, driven by Group Sustainability Board

New Management Board remuneration system to be presented at AGM, includes ESG component

Supervisory Board elections on AGM agenda

Meet the Management – Conference Call Series

Agenda

31

Fresenius Group: Q4/20 profit and loss statement

All growth rates in constant currency (cc) Before special items Net income attributable to shareholders of Fresenius SE & Co. KGaA

Key Messages

Successful despite unprecedented challenges: FY/20 Guidance achieved

Accelerated COVID-19 related excess mortality of dialysis patients

Expected recovery of elective treatments drives organic growth

2020 2021 Mid-term

Group-wide cost-efficiency program to be initiated

28th consecutive dividend increase proposed

Ongoing recovery in Europe and Emerging Markets to drive solid top-line growth

FY/21 expected to be marked by COVID-19 with projected recovery in H2/21

Growth to accelerate: Medium-term growth targets confirmed

COVID-19 Assumptions for Guidance FY/21

Current burdens and constraints caused by COVID-19 expected only to begin to recede in H2/21

The guidance does not reflect impacts from potential containment measures without appropriate compensation for the health care sector

Continuously advancing vaccination program in the company's relevant markets

For H2/21, we expect a significant improvement primarily in elective treatments due to continuously increasing level of vaccination coverage

FY/21 Financial Outlook by Business Segment

€m (except	otherwise stated)		FY/20 Base	FY/20	FY/21e
		Sales growth (org)	6,976	4%	Low-to-mid single-digit %
	EBIT growth (cc)	1,095	-6%	Stable to low single-digit %
		Sales growth (org)	9,818	4%	Low-to-mid single-digit %
	EBIT growth (cc)	1,025	0%	Mid-to-high single-digit %
		Sales growth (org)	2,068	-8%	Mid-to-high single-digit %
	EBIT growth (cc)	29	-79%	High double digit €m

Before special items and including estimated COVID-19 effects

For a detailed overview of special items please see the reconciliation tables provided on our website https://www.fresenius.com/results-center.

FY/21 Financial Guidance

€m (except otherwise stated)		FY/20 Base	FY/20	FY/21
	Sales growth (cc)	36,277	5%	Low-to-mid single-digit %
	Net income growth (cc)	1,796	-3%	At least broadly stable

Before special items and including estimated COVID-19 effects Net income attributable to shareholders of Fresenius SE & Co. KGaA

For a detailed overview of special items please see the reconciliation tables provided on our website https://www.fresenius.com/results-center.

Agenda

37

Fresenius Group: Easing COVID-19 impact whilst regaining business momentum

	Main drivers for FY/21	Expected COVID effects
	Higher mortality rate amongst dialysis patients	Significant
	Elective treatments in China already from Q1/21 onwards almost at pre-COVID levels; Recovery in NAM expected in H2/21; Headwinds in H1/21 partially compensated by higher demand for COVID-related products	Moderate	Moderate	Slight impact	Slight impact
	Whilst H1/21 is expected to be marked by a lack of elective treatments, significant improvement are expected in H2/21 due to continuous vaccination of population.	Significant	Significant	Slight impact	Slight impact
	Improved demand for post-acute care services due to recovery of elective treatments in H2/21 Project business expected to be impacted by travel restrictions in H1/21, gradual recovery in H2/21	Significant	Significant	Moderate	Slight impact
	H1/21 is expected to be significantly negative impacted by COVID-19; for H2/21 an improvement primarily in elective treatments is expected	Significant	Significant	Moderate	Slight impact
These assumptions are subject to considerable uncertainty.		Q1	Q2	Q3	Q4

Fresenius Kabi: Headwinds in the US expected to continue, whilst Europe is projected for a gradual recovery and China is anticipated to be back to healthy growth

H1/21 expected to still see fewer elective treatments and competitive pressure

Melrose Park:

• All manufacturing sites are fully operational
• No product launches from this plant in FY/21 expected

15+ product launches planned in FY/21

Ongoing recovery of elective treatments expected alongside increasing vaccination coverage of population

Ongoing roll-out and ramp-up of biosimilars business contributes to organic sales growth

North America Europe Emerging Markets

China expected to leave COVID-19 effects behind; more pricing pressure due to tender system combined with dynamic volume growth expected to lead to healthy organic growth in FY/21

Launch of new formulations and applications in the field of parenteral and enteral nutrition in China

Further roll-out of IV drug portfolio in China

Fresenius Kabi: Building the platform for decisive US growth through strategic initiatives to diversify and differentiate portfolio, and expand in new therapies and channels

Fresenius Kabi: Q4 & FY/20 Organic Sales Growth by Regions

€m	Q4/20	Δ YoY organic	FY/20	Δ YoY organic
North America	549	-3%	2,376	0%
Europe	680	9%	2,458	6%
Emerging Markets	586	15%	2,142	6%
Total sales	1,815	7%	6,976	4%

Fresenius Kabi: Q4 & FY/20 Organic Sales Growth by Product Segment

€m	Q4/20	Δ YoY organic	FY/20	Δ YoY organic
IV Drugs	697	1%	2,921	3%
Infusion Therapy	242	3%	810	-3%
Clinical Nutrition	528	15%	1,945	7%
Medical Devices/ Transfusion Technology	348	10%	1,300	7%
Total sales	1,815	7%	6,976	4%

Fresenius Kabi: Q4 & FY/20 EBIT Growth

€m	Q4/20	Δ YoY cc	FY/20	Δ YoY cc
North America Margin	125 22.8%	-33% -1,100 bps	785 33.0%	-12% -450 bps
Europe	85	-1%	355	+9%
Margin	12.5%	-210 bps	14.4%	+20 bps
Emerging Markets	153	+29%	471	+5%
Margin	26.1%	+330 bps	22.0%	+10 bps
Corporate and Corporate R&D	-127	2%	-516	-4%
Total EBIT	236	-10%	1,095	-6%
Margin	13.0%	-310 bps	15.7%	-170 bps

All figures before special items Margin growth at actual rates For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https://www.fresenius.com/results-center. Fresenius Helios: Interlinked business model with leading market position offers a strong foundation to leverage network efficiencies and accelerate growth opportunities

From prevention to intervention

Serving patients for all healthrelated demands

Reach patients at all levels of care: Prevention, Occupational medicine, MVZ, Hospitals

Demand for ORP services in Spain accelerated due to COVID-19

Increase digital connect with patients:

• Patient portals
• Video consultations
• Curalie with digital features for chronically ill

Stable reimbursement (2021 DRG inflator set at 2.53%)

Cost pressure from the regulator to be partially mitigated

Efficiency gains from increasing digitalization of clinical processes

Fields of innovation Regulatory environment Opportunities for growth

Greenfield & expansion projects Focus on new set-up of MVZs Expand fertility services offering Selective acquisitions

Fresenius Helios: Acquisition of Eugin Group makes Fresenius Helios a leading international provider of fertility services with significant growth opportunities

Acquisition adds global network of fertility clinics

Acquisition complements existing Fresenius Helios footprints in Germany, Spain and LatAm

Global fertility market offers significant growth opportunities and consolidation potential

Accretive to Group net income from FY/21 onwards

Strong presence in Europe, LatAm, and U.S.

Valuation1 of €430m corresponds to ~11.4x at the mid-point of the 2021 EBITDA range.

¹ Including approx. €80 million of minority interests and assumed debt

2019 2021e

€m €35 to €40 million

0

10

20

30

40

EBITDA

€31 million

Largest markets: U.S., Spain, Brazil, Italy and Sweden

Fresenius Helios: COVID-19 Update

Fresenius Helios: Q4 & FY/20 Key Financials

€m	Q4/20	Δ YoY cc	FY/20	Δ YoY cc
Total sales	2,637	9%1	9,818	4%1
Thereof Helios Germany	1,637	8%1	6,340	6%1
Thereof Helios Spain	999	11%1	3,475	2%1
Total EBIT Margin	328 12.4%	13% -10 bps	1,025 10.4%	0% -70 bps
Thereof Helios Germany Margin	157 9.6%	10% -10 bps	602 9.5%	4% -20 bps
Thereof Helios Spain Margin	159 15.9%	19% 20 bps	420 12.1%	-5% -140 bps
Thereof Corporate	12	--	3	--

¹ Organic growth

For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https://www.fresenius.com/results-center.

Fresenius Helios: Key Metrics

	FY/20	FY/19	Δ
No. of hospitals Germany - Acute care hospitals	89 86	86 83	3% 4%
No. of hospitals Spain (Hospitals)	52	50	4%
No. of beds Germany - Acute care hospitals	29,978 29,451	28,907 28,380	4% 4%
No. of beds Spain (Hospitals)	7,936	7,288	9%
Admissions Germany (acute care)	1,044,959	1,206,654
Admissions Spain (including outpatients)	15,037,804	15,396,051

48

Fresenius Vamed: Gradual recovery of business ahead; good order intakes despite COVID-19

COVID-19 headwinds to ease in the course of 2021

Easing of travel restrictions expected for H2/21

Lack of electives treatments – expected to recover in H2/21

Reduced capacity at post-acute care to last over H1/21

Technical services business to remain robust

Recovery of project business in Q4/20 – solid order book

Order intake in Q4/20 13% above prior year; overall order intake in FY/20 decreased by 23% versus prior year

Major turnkey contract in Q4/20:

• Severodonetsk General Hospital in Ukraine

Barclays Global Healthcare Conference, March 11, 2021 © Fresenius SE & Co. KGaA Investor Relations & Sustainability 49

Fresenius Vamed: Q4 & FY/20 Key Financials

€m	Q4/20	Δ YoY cc	FY/20	Δ YoY cc
Total sales Thereof organic sales	577	-22% -22%	2,068	-6% -8%
Service business	372	-1%	1,435	3%
Project business	205	-44%	633	-22%
Total EBIT	39	-42%	29	-79%
Order intake1	648	13%	1,010	-23%
Order backlog1			3,055	7%2

¹ Project business only ² Versus December 31, 2019

Fresenius Group: Q4/20 Key Financials

€m	Q4/201	special items	Q4/20 reported	YoY cc1 Δ
Sales	9,304	-	9,304	5%
EBIT	1,251	-227	1,024	2%
Net interest	-159	3	-156	9%
Income taxes	-263	8	-255	-8%
Net income2	494	-84	410	2%

¹ Before special items

2 Net income attributable to shareholders of Fresenius SE & Co. KGaA

For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https://www.fresenius.com/results-center.

Fresenius Group: Calculation of Noncontrolling Interests

€m	FY/20	FY/19
Earnings before tax and noncontrolling interests	3,958	3,974
Taxes	-914	-925
Noncontrolling interests, thereof	-1,248	-1,170
Fresenius Medical Care net income not attributable to Fresenius (Q4/20: ~68%)	-922	-849
Noncontrolling interest holders in Fresenius Medical Care	-271	-239
Noncontrolling interest holders in Fresenius Kabi (-€44 m), Fresenius Helios (-€8 m), Fresenius Vamed (-€3 m)	-55	-82
Net income attributable to Fresenius SE & Co. KGaA	1,796	1,879

Before special items For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https://www.fresenius.com/results-center.

Fresenius Group: Cash Flow

€m	Q4/20	LTM Margin	Δ YoY
Operating Cash Flow	1,390	18.1%	8%
Capex (net)	-800	-6.6%	5%
Free Cash Flow	590	11.5%	33%
(before acquisitions and dividends)
Acquisitions (net)	-202
Dividends	-59
Free Cash Flow (after acquisitions and dividends)	329	6.8%	--

Fresenius Group: Estimated COVID-19 Effects Q4/20 & FY/20

	as	Growth cc reported incl. COVID-19	Estimated COVID-19 impact cc
	Q4/201	FY/201	Q4/201	FY/201
Sales	+5%	+5%	-2% to -3%	-2% to -3%
Net income2	+2%	-3%	-1% to -5%	-5% to -9%

¹ Before special items

2 Net income attributable to shareholders of Fresenius SE & Co. KGaA

Fresenius Group: Proven Track Record of Deleveraging

Net Debt/EBITDA1

2002-2019 excluding IFRS 16

¹ At actual FX rates from 2002 to 2010 and at average FX rates from 2011 onwards, for both Net Debt and EBITDA; before special items; pro forma closed acquisitions/divestitures

² Pro forma excluding advances made for the acquisition of hospitals from Rhön-Klinikum AG

³ Including IFRS 16

Fresenius Group: Major Long-Term Debt Maturities1 Well-balanced Maturity Profile

¹ As of December 31, 2020 and based on utilization of major financing instruments, excl. Commercial Paper of EUR 50m

Fresenius Group: Sales by Business Segment – FX, Acquisitions/Divestitures Effects Q4/20

€m	Q4/20	Q4/19	Growth at actual rates	Currency translation effects	Growth at constant rates	Organic growth	Acquisi tions	Divesti tures/ Others
Fresenius Medical Care	4,400	4,580	-4%	-8%	4%	1%	3%	0%
Fresenius Kabi	1,815	1,766	3%	-5%	8%	7%	0%	1%
Fresenius Helios	2,637	2,344	13%	0%	13%	9%	4%	0%
Fresenius Vamed	577	737	-22%	0%	-22%	-22%	0%	0%
Total	9,304	9,311	0%	-5%	5%	2%	3%	0%

57

Fresenius Group: Sales by Business Segment – FX, Acquisitions/Divestitures Effects FY/20

€m	FY/20	FY/19	Growth at actual rates	Currency translation effects	Growth at constant rates	Organic growth	Acquisi tions	Divesti tures/ Others
Fresenius Medical Care	17,859	17,477	2%	-3%	5%	3%	3%	-1%
Fresenius Kabi	6,976	6,919	1%	-3%	4%	4%	0%	0%
Fresenius Helios	9,818	9,234	6%	-1%	7%	4%	3%	0%
Fresenius Vamed	2,068	2,206	-6%	0%	-6%	-8%	2%	0%
Total	36,277	35,409	2%	-3%	5%	3%	2%	0%

58

Fresenius Group: Solid Balance Sheet Structure

• Healthy Equity and Liability Split

• Strong equity ratio of >40% on average
• Equity ratio kept in narrow range despite rapid growth of Fresenius Group

Growth	Profitability	Liqudity	Capital efficiency	Capital management
Sales growth (in constant currency)	Operating income (EBIT) +/ - Financial result	Operating cash flow ÷ Sales	EBIT Income taxes	Net debt ÷ EBITDA
Sales growth (organic)	- Income taxes - Minority interests = Net income EBIT growth (in constant currency) Net income growth (in constant currency)	= Cash flow margin	= NOPAT ÷ Invested capital = ROIC1 EBIT ÷ Operating assets = ROOA1	= Leverage ratio

1 Does not reflect a core performance indicator

Fresenius Group1: Performance Indicators 5-year overview

	Targets 20202	2020	2019	2018	2017	2016
Sales growth (in constant currency)	+3% to +6%	5%	6%	6%	16%	6%
Net income3 growth (in constant currency)	-4% to +1%	-3%	0%	7%	21%	13%
Liquidity and capital management
Cash flow margin	12% to 14%	18.1%	12.0% /9.9%4	11.2%	11.6%	12.2%
/ EBITDA5 Net debt	Around the top-end of 3.0x – 3.5x6	3.44x	3.14x4 3.61x/	2.71x	2.84x	2.33x
Capital efficiency
Return on invested capital (ROIC)7	At 2019 level	6.5%	/7.4%4 6.7%	8.3%	8.0%	8.5%
Return on operating assets (ROOA)7	At 2019 level	7.3%	7.6% /8.2%4	9.0%	9.4%	10.0%

¹ Growth rates are based on the assumptions of the respective annual forecasts and are adjusted for special items and, if applicable, other effects affecting the underlying growth (adjustments to new accounting

standards, acquisitions / divestments, acquisition costs, or cost-saving programs).

² Including estimated COVID-19 effects (updated October 2020)

³ Net income attributable to shareholders of Fresenius SE & Co. KGaA

⁴ Excluding IFRS 16 effect

⁵ Both net debt and EBITDA calculated at LTM average exchange rates; before special items, pro forma closed acquisitions/divestitures

⁶ Around the top-end of the self-imposed target range of 3.0x to 3.5x; excluding further potential acquisitions

⁷ Before special items, pro forma acquisitions

Business segments1: Performance Indicators 5-year overview

	Targets 20202	2020	2019	2018	2017	2016
Fresenius Medical Care
Sales growth (in constant currency)	Mid-to-high single-digit %-range	5%	5%	4%	9%	7%
Net income growth 3,4 (in constant currency)	Mid-to-high single-digit %-range	12%	-2%	4%	7%	16%
Fresenius Kabi
Sales growth (organic)	+ 2% to +5%	4%	4%	7%	7%	5%
EBIT growth (in constant currency)	- 6% to -3%	-6%	3%	2%	8%	5%
Fresenius Helios
Sales growth (organic)	+ 1% to +4%	4%	5%	3%	4%	4%
EBIT growth (in constant currency)	Broadly stable	0%	-4%	0%	54%	7%
Fresenius Vamed
Sales growth (organic)	~ - 10%	-8%	16%	16%	6%	5%
EBIT growth (in constant currency)	Positive absolute EBIT	€ 29 million	19%	45%	10%	8%

¹ Growth rates are based on the assumptions of the respective annual forecasts and are adjusted for special items and, if applicable, other effects affecting the underlying growth (adjustments to new accounting standards, acquisitions / divestments, acquisition costs, or cost-saving programs).

² Including estimated COVID-19 effects (updated October 2020)

³ Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA

⁴ Special items are effects (when consolidated at the Fresenius Group: special items), that are unusual in nature and were not foreseeable or not foreseeable in size or impact at the time of giving guidance.

Financial Calendar / Contact

Financial Calendar Contact

06 May 2021	Results Q1/21
21 May 2021	Annual General Meeting
30 July 2021	Results Q2/21
02 November 2021	Results Q3/21

Please note that these dates could be subject to change.

Investor Relations & Sustainability Fresenius SE & Co. KGaA phone: +49 6172 608-2485 e-mail: ir-fre@fresenius.com

For further information and current news: www.fresenius.com

www.twitter.com/fresenius\_ir

www.linkedin.com/company/fresenius-investor-relations